The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27

Highlights ► Vaccination with HSV gD, gB and ICP27 provided protection from HSV-2 challenge. ► Vaccination with VP13/14 or VP22 did not provide protection. ► Combining ICP27 with gD or gB provided a greater level of protection than any single antigen. ► Adding ICP27 to enhance T cell responses can i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-12, Vol.30 (52), p.7529-7535
Hauptverfasser:	Bright, Helen, Perez, David Lucia, Christy, Clare, Cockle, Paul, Eyles, Jim E, Hammond, Daisy, Khodai, Tansi, Lang, Susanne, West, Kate, Loudon, Peter T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviruses Allergy and Immunology Amino acids Animals Antibodies, Viral - blood antigens Deoxyribonucleic acid Disease Models, Animal DNA Female Herpesviridae Infections - immunology Herpesviridae Infections - pathology Herpesviridae Infections - prevention & control Herpesvirus 2, Human - genetics Herpesvirus 2, Human - immunology Herpesvirus Vaccines - administration & dosage Herpesvirus Vaccines - immunology HSV-2 ICP27 Immediate-Early Proteins - genetics Immediate-Early Proteins - immunology Lymphocytes Mice Mice, Inbred BALB C Mortality neutralization neutralizing antibodies Peptides recombinant vaccines Severity of Illness Index Studies T-lymphocytes T-Lymphocytes - immunology Vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - immunology Values Viral Envelope Proteins - genetics Viral Envelope Proteins - immunology Viral Proteins - genetics Viral Proteins - immunology Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Vaccination with HSV gD, gB and ICP27 provided protection from HSV-2 challenge. ► Vaccination with VP13/14 or VP22 did not provide protection. ► Combining ICP27 with gD or gB provided a greater level of protection than any single antigen. ► Adding ICP27 to enhance T cell responses can improve the efficacy of gB- or gD-based HSV vaccines.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2012.10.046